UK GLP-1 prices & evidence, made clearer.Our comparison standards
The evidence comparator

Different medicines.
The detail that matters.

Put up to four medicines side by side. See the evidence, day-to-day differences and current first-order price references — with the caveats kept in view.

Build your comparison

Choose up to 4
Core medicines
Other medicines, diabetes treatments & research

These are separate categories, not interchangeable UK weight-management options. Read each authorisation and evidence note.

Other medicines
Evidence, before estimates

What does a trial average actually tell you?

It describes a particular study group at a particular time. It does not tell you how much weight you will lose, or which medicine will suit you. Compare selected medicines to open the full records.

A useful starting point

Four formulations. Four sets of instructions.

Mounjaro

Tirzepatide · Once weekly

Acts at GIP and GLP-1 receptors involved in appetite and blood-glucose regulation.

Can be injected with or without food.

Read the complete guide

Wegovy injection

Semaglutide · Once weekly

A GLP-1 receptor agonist that affects appetite regulation and glucose-dependent insulin secretion.

Can be injected with or without food.

Read the complete guide

Wegovy tablets

Semaglutide · Once daily

Oral semaglutide acts at GLP-1 receptors. Its formulation enables absorption, which depends on the administration conditions.

Take whole after at least eight hours fasting with no more than 120 mL water, then wait at least 30 minutes before food, drink or other oral medicines.

Read the complete guide

Foundayo

Orforglipron · Once daily

A small-molecule, non-peptide GLP-1 receptor agonist. It is a different active ingredient from tirzepatide.

Can be taken at any time, without food or water restrictions; swallow the tablet intact.

Read the complete guide

How to read the evidence

The comparator includes SURMOUNT-1, STEP 1, STEP UP, OASIS 4, ATTAIN-1 and SURMOUNT-5. It keeps each study’s population, duration, dose and estimand attached to the reported result. An estimand describes the treatment effect a trial is trying to measure, including how treatment discontinuation is handled.

SURMOUNT-5 is a direct comparison of maximum tolerated tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg injections. Its findings do not compare tirzepatide with Wegovy 7.2 mg, Wegovy tablets or Foundayo. Separate placebo-controlled trials cannot establish a league table between those medicines.

No invented dose results

There are no interpolated Mounjaro results for 7.5 or 12.5 mg, and no invented Foundayo result for 14.5 mg. ATTAIN-1 used research capsules; where the UK product information establishes a tablet equivalent, that distinction is shown. A research dose is not an instruction for your prescription.

UK availability is a separate question

A marketing authorisation, NHS funding recommendation, local eligibility and pharmacy stock are different things. Research-only entries are labelled. Rybelsus is shown as a diabetes medicine, not as another name for Wegovy tablets. Qsymia’s presence is not a claim that it is authorised in the UK.

Evidence checked 2026-11-20. AI-assisted source review; independent clinical review is pending. Price methodology · Editorial policy.

Original evidence sources
  1. Mounjaro KwikPen: UK Summary of Product Characteristics
  2. Mounjaro KwikPen: UK patient leaflet
  3. Wegovy injection: UK Summary of Product Characteristics
  4. MHRA authorisation of the 7.2 mg Wegovy dose for adults with obesity
  5. Wegovy tablets: UK Summary of Product Characteristics
  6. Wegovy tablets: UK patient leaflet
  7. MHRA authorisation of Wegovy tablets, 11 June 2026
  8. Foundayo: UK Summary of Product Characteristics, text revised 3 November 2026
  9. Foundayo: UK patient leaflet
  10. MHRA authorisation of Foundayo, 10 August 2026
  11. NICE committee material: semaglutide and liraglutide access criteria
  12. SURMOUNT-1: sponsor report identifying both estimands
  13. STEP 1: once-weekly semaglutide in adults with overweight or obesity
  14. STEP UP: semaglutide 7.2 mg in adults with obesity
  15. ATTAIN-1: original orforglipron obesity trial report
  16. SURMOUNT-5: tirzepatide compared with semaglutide
  17. SURMOUNT-5: sponsor report confirming treatment-regimen estimand
  18. MHRA strengthened pancreatitis warnings, 29 January 2026
  19. MHRA semaglutide and NAION update, 5 February 2026
  20. Lilly medical information: investigational retatrutide and TRIUMPH-1
  21. Novo Nordisk: investigational CagriSema, 14 November 2026
  22. Saxenda: UK Summary of Product Characteristics
  23. Mysimba: manufacturer-hosted UK product information, July 2023
  24. NICE TA494: naltrexone-bupropion is not recommended
  25. EMA review of Mysimba and long-term cardiovascular uncertainty
  26. Xenical 120 mg: UK Summary of Product Characteristics
  27. Rybelsus new formulation: UK Summary of Product Characteristics
  28. MHRA Rybelsus formulation transition and medication-error warning
  29. Qsymia: US prescribing information revised March 2026
  30. Irish HPRA authorisation record for Qsiva